RESUMEN

OBJECTIVE: We aimed to evaluate the frequency of Post Traumatic Stress Disorder (PTSD), to determine the risk factors, and to monitor the change of symptoms after 6 months among individuals who survived the avalanche disaster in Van. METHOD: Face-to-face interviews were conducted with 35 people who were rescued from two consecutive avalanche disasters in Van 2 months and 6 months after the avalanche disaster. The socio-demographic and clinical data of the cases were evaluated. The Post Traumatic Stress Disorder Symptom Scale-Self Report version (PSS-SR) and clinical interviews were used for PTSD diagnosis. The level of trauma was assessed by using the Impact of Event Scale (IES). RESULTS: All participants were rescuers who went to the avalanche site for rescue mission. Of the cases, 16 were volunteers from the local community and 19 were professional rescuers. The frequency of PTSD was 71.4% in the early assessment, and 57.1% in the long term. Staying in avalanche for more than 30 minutes, the absence of a history of disaster exposure and being in the group of volunteers were found to increase the risk for PTSD development. CONCLUSION: There is a high risk of developing PTSD as a result of an avalanche. People who will intervene with the disasters should be educated and prepared in terms of preventing negative psychological consequences of the disaster. The relationship between the severity of trauma and PTSD was replicated in our study.

Asunto(s)

RESUMEN

OBJECTIVE: Sleep problems are common in patients with psychotic disorders, especially schizophrenia. Although pharmacological methods are at the forefront of treatment, this method has some drawbacks. Cognitive behavioral therapy for insomnia (CBT-I) is an option for the treatment of individuals with insomnia. In recent years, there has been an increasing interest in its use in patients with psychotic disorders. This meta-analysis aims to evaluate the effectiveness of CBT-I on sleep problems in patients with psychotic disorders. METHODS: A systematic search was conducted using PubMed, Scopus, and EBSCO (MEDLINE) databases to identify relevant studies. The study included RCTs and uncontrolled studies that focused on participants diagnosed with schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorders not otherwise specified, bipolar disorders, or unipolar depression with psychotic features, who had sleep problems for at least one month, and who were receiving treatment. The initial search yielded 246 studies, and eight studies were selected for the meta-analysis after screening and applying inclusion and exclusion criteria.The statistical analysis was conducted using the R software. RESULTS: CBT-I significantly ameliorates insomnia and sleep quality in patients with psychotic disorders during short and long-term periods. In addition to this, CBT-I leads to a significant improvement in psychotic symptoms in the short-term period and contributes significantly to the improvement in mental well-being in both short and long-term periods. CONCLUSIONS: CBT-I is an effective and valuable method for sleep problems in patients with psychotic disorders and its use is recommended to be widespread.

RESUMEN

Biological, genetic and psychosocial factors may play a role in the aetiology of bipolar mood disorder (BPD). BPD episodes might be triggered by isotretinoin, a retinoid derivative of vitamin A with a role in cellular proliferation and differentiation. Due to its association with depression, suicidal ideation and suicide attempts, American Food and Drug Administration (FDA) issued a placement of a label warning for isotretionin. Personal or family history of psychiatric disorders was emphasized in the literature for the risk of mood episodes following isotretionin treatment. Here we aim to present the case of an 18- year old young male adult, without personal or family history of a psychiatric disorder, who developed psychotic mania within the first week of isoretinoin which was prescribed for acne vulgaris. Psychotic mania symptoms receded within one week after starting olanzapine (10 mg/day). We believe this case is significant in demonstrating the occurence of a manic episode after isoretinoin in individuals lacking a personal or family history of psychiatric diagnoses.

Asunto(s)

RESUMEN

Biological, genetic and psychosocial factors may play a role in the aetiology of bipolar mood disorder (BPD). BPD episodes might be triggered by isotretinoin, a retinoid derivative of vitamin A with a role in cellular proliferation and differentiation. Due to its association with depression, suicidal ideation and suicide attempts, American Food and Drug Administration (FDA) issued a placement of a label warning for isotretionin. Personal or family history of psychiatric disorders was emphasized in the literature for the risk of mood episodes following isotretionin treatment. Here we aim to present the case of an 18- year old young male adult, without personal or family history of a psychiatric disorder, who developed psychotic mania within the first week of isoretinoin which was prescribed for acne vulgaris. Psychotic mania symptoms receded within one week after starting olanzapine (10 mg/day). We believe this case is significant in demonstrating the occurence of a manic episode after isoretinoin in individuals lacking a personal or family history of psychiatric diagnoses.

Asunto(s)

RESUMEN

Diverse dermatological side effects in relation to using psychotropic agents, include the serious outcomes as hypersensitivity and StevensJohnson syndrome as well as milder forms as ecchymosis and hair loss. Whereas hair loss is frequently associated with mood stabilizers, rarely ,it is also attributed to antidepressants. Selective serotonin reuptake inhibitors (SSRIs) which are the first choice treatment for depression, anxiety disorders and obsessive-compulsive spectrum disorders, are the most commonly used antidepressant drugs. Psychiatric comorbidities have been known in many dermatological diseases and their treatment have positive effects on the course and outcome as well as on the adaptation process to the disease. Due to their favorable side effect profile, for comorbid cases SSRIs are frequently used. Here we present a case of hair loss during paroxetine in a 24-year-old male with social anxiety disorder. In this case the hair loss improved after discontinuing and recurred after resuming paroxetine. After replacing paroxetine with sertraline, another SSRI, alopecia did not recur.

Asunto(s)

RESUMEN

Bupropion is an effective treatment for major depressive disorder and smoking cessation. In this paper, we present a case report about dystonia in the head and the neck after epileptic seizures due to 4200 mg of extended-release bupropion intake, and we aim to take attention to the rare neuropsychiatric side effects that may occur after the use of high doses of bupropion.

Asunto(s)

RESUMEN

OBJECTIVE: In this study, we aimed to the Self-Stigma of Depression Scale (SSDS), which evaluates self-stigmatization that can prevent both treatment consultation and compliance by depressed patients run Turkish adaptation, validity and reliability study of. METHOD: The study included a total of 173 subjects consisting of 131 outpatients of the Psychiatry Polyclinic with past or recent major depression disorder (MDD) diagnosis and 42 non-depressed outpatients consulting the Geriatrics Polyclinics for other medical complaints. Each participant was evaluated with the Structured Clinical Interview for DSM IV Axis I Disorders (SCID-I), the Standardized Mini Mental State Examination (MMSE), the Turkish Self-Stigma of Depression Scale (SSDS-TR) and the Beck Depression Inventory (BDI). The MDD patients were further evaluated with the Internalized Stigma of Mental Illness (ISMI) scale. Test-retest reliability of the SSDS-TR was assessed with 27 participants 8-12 weeks after the first test. All analyses were carried out using the IBM-SPSS Statistics version 25 and the IBM SPSS AMOS version 25. RESULTS: In the exploratory factor analysis, the factor structure of SSDS TR differed from the original form. The structural validity of the 4-factor model formed after excluding one problematic item was tested by confirmatory factor analysis and proven to meet the goodness of fit criteria. The Cronbach's α coefficient of the SSDS-TR was 0.847, and a moderate correlation (r=0.436 p=0.023) was obtained by the test-retest analysis. The SSDS-TR scores moderately correlated with the ISMI scores (r=0.485, p<0.001) and weakly correlated with the BDI scores (r=0.246, p<0.001). CONCLUSION: The SSDS-TR formed by excluding one item from the original scale was demonstrated to be a valid and reliable psychometric tool and is expected to fill a gap in the assessment of self stigmatization of MDD patients in Turkey.

Asunto(s)

Asunto(s)